← Leaderboards
Yunlong Huang
Ting Therapeutics, Inc.
$2,977,591
Attributed
$2,977,591
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.1M · FY2015–24$2M$1.5M$1M$500K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$2,977,591 · 4
By mechanism
R44$2,406,341 · 2
R21$420,750 · 1
R03$150,500 · 1
Top collaborators
No co-investigators on record.
Most similar at Ting Therapeutics, Inc.
Same institution · by research overlap
- Marisa L. Zallocchi$2,621,481
Others in their field
Top investigators on “Pharmaceutical Preparations”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$266,816,120
- Leonard Freedman · Leidos Biomedical Research, Inc.$240,520,687
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$196,976,947
- Lawrence Corey · Fred Hutchinson Cancer Center$196,976,947
Research focus
Pharmaceutical PreparationsMouse ModelClinical TrialsIn VivoAntineoplastic AgentsFutureNeoplastic CellDrug KineticsToxic EffectTumorRegimenIn VitroBloodAnimal ModelCommercializationCochleaAntioxidantsCommercial ApplicationContractsCisplatin Induced Hearing LossClinical TreatmentAuditory Brainstem ResponsesAuditoryAnticancer Activity
Grant awards (11)
Preclinical evaluation of an otoprotectant TT002$326,371
R44 · FY2024 · DC · contact PI
CDK2 inhibitors for protecting hearing loss$176,763
R44 · FY2024 · DC · contact PI
CDK2 inhibitors for protecting hearing loss$174,684
R44 · FY2024 · DC · contact PI
Preclinical evaluation of an otoprotectant TT002$1
R44 · FY2024 · DC · contact PI
Preclinical evaluation of an otoprotectant TT002$565,771
R44 · FY2023 · DC · contact PI
CDK2 inhibitors for protecting hearing loss$541,332
R44 · FY2023 · DC · contact PI
Preclinical evaluation of an otoprotectant TT002$621,419
R44 · FY2022 · DC · contact PI
Eradication of CNS HIV reservoirs through a first-in-class anti-tumor agent ONC201$191,250
R21 · FY2021 · MH · contact PI
Eradication of CNS HIV reservoirs through a first-in-class anti-tumor agent ONC201$229,500
R21 · FY2020 · MH · contact PI
Targeting FOX03a with TIC10 to eradicate HIV-1 from CNS reservoirs$75,250
R03 · FY2016 · NS · contact PI
Targeting FOX03a with TIC10 to eradicate HIV-1 from CNS reservoirs$75,250
R03 · FY2015 · NS · contact PI